View on Pubmed.gov 26498689 | View on doi.org 10.18632/oncota...
Key contribution of eIF4H-mediated translational control in tumor promotion.
- INSERM U1037, CRCT, Cancer Research Center of Toulouse, Toulouse, France.
- Toulouse University, Paul Sabatier, Toulouse, France.
- INSERM U1037, CRCT, Cancer Research Center of Toulouse, Toulouse, France. Toulouse University, Paul Sabatier, Toulouse, France.
- Department of Thoracic Surgery, Rangueil-Larrey Hospital, Toulouse, France.
- Department of Pathology, CHU Rangueil, Toulouse, France.
- Inserm US006 Crefre, Toulouse, France.
- San Raffaele Scientific Institute, Milano, Italy.
- Clinical Trial Office, Cellule Biostatistique Institut Universitaire du Cancer Toulouse, Toulouse, France.
- INSERM U1037, CRCT, Cancer Research Center of Toulouse, Toulouse, France. Department of Pathology, CHU Rangueil, Toulouse, France.
- Department of Respiratory Medicine, Broomfield Hospital, Chelmsford, Essex, UK.
- Department of Thoracic Oncology, Papworth Hospital, Cambridge, UK.
- Department of Pathology, Institut Universitaire du Cancer, Toulouse, France.
Abstract
Dysregulated expression of translation initiation factors has been associated with carcinogenesis, but underlying mechanisms remains to be fully understood. Here we show that eIF4H (eukaryotic translation initiation factor 4H), an activator of the RNA helicase eIF4A, is overexpressed in lung carcinomas and predictive of response to chemotherapy. In lung cancer cells, depletion of eIF4H enhances sensitization to chemotherapy, decreases cell migration and inhibits tumor growth in vivo, in association with reduced translation of mRNA encoding cell-proliferation (c-Myc, cyclin D1) angiogenic (FGF-2) and anti-apoptotic factors (CIAP-1, BCL-xL). Conversely, each isoform of eIF4H acts as an oncogene in NIH3T3 cells by stimulating transformation, invasion, tumor growth and resistance to drug-induced apoptosis together with increased translation of IRES-containing or structured 5'UTR mRNAs. These results demonstrate that eIF4H plays a crucial role in translational control and can promote cellular transformation by preferentially regulating the translation of potent growth and survival factor mRNAs, indicating that eIF4H is a promising new molecular target for cancer therapy.
References
RNA. 2001 Mar;7(3):382-94
Biochem Pharmacol. 2011 Mar 15;81(6):713-22
J Biol Chem. 2001 Aug 17;276(33):30914-22
J Biol Chem. 2003 Oct 10;278(41):39330-6
Cited by 37 citations (total)
Journal Article Research Support, Non-U.S. Gov't
A new semi-supervised learning model combined with Cox and SP-AFT models in cancer survival analysis.
Electronic publication date July 2, 2019
Hua Chai [...] Yong Liang et al.
Gene selection is an attractive and important task in cancer survival analysis. Most existing supervised learning methods can only use...
Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review
Translation initiation factors and their relevance in cancer.
Electronic publication date March 6, 2019
Columba de la Parra [...] Robert J Schneider et al.
Deregulation of several translation initiation factors occurs in numerous types of cancers. Translation initiation factors are not merely ancillary players...
Conflict of interest statement
MeSH
- •
- •
- •
- •
- •
- •
- •
Specialties
- •
- •
- •
- •
- •
- •
- •
Substances
- •
- •
- •
- •